AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17134031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy for 1 week
Number of subjects: 16
Study 17134031 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet therapy or oral hypoglycemic agents)
Number of subjects: 16
Study 14673602 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid-rich diet (high oleic acid sunflower oil)
Number of subjects: 14
Study 14673602 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmolein diet (rich in palmitic acid)
Number of subjects: 14
Study 10996359 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 6
Study 9310011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg
Number of subjects: 80
Study 9310011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Number of subjects: 80
Study 9310011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1000 mg
Number of subjects: 80
Study 9310011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1500 mg
Number of subjects: 80
Study 9310011 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid 300 mg
Number of subjects: 80
Study 9310011 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 80
Study 8443038 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment (radiolabelled with technetium‐99m tin colloid)
Number of subjects: 7
Study 8443038 — intervention group
Group type: COMPARATOR
Intervention: 0.3% w/v HPMC solution (radiolabelled with technetium‐99m diethylenetriaminepentaacetic acid)
Number of subjects: 7
Study 8443038 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment
Number of subjects: 7
Study 8443038 — intervention group
Group type: COMPARATOR
Intervention: 0.3% w/v HPMC solution
Number of subjects: 7
Study 3513594 — intervention group
Group type: EXPERIMENTAL
Intervention: levobunolol 0.5%
Number of subjects: 92
Study 3513594 — intervention group
Group type: EXPERIMENTAL
Intervention: levobunolol 1%
Number of subjects: 92
Study 3513594 — intervention group
Group type: COMPARATOR
Intervention: timolol 0.5%
Number of subjects: 92
Study 31129911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cangrelor
Number of subjects: 100
Study 31129911 — intervention group
Group type: COMPARATOR
Intervention: Oral ticagrelor
Number of subjects: 100
Study 28681435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide-based induction therapy
Number of subjects: 60
Study 28681435 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide-naive controls
Number of subjects: 60
Study 25741582 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste
Number of subjects: 383
Study 25741582 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 383
Study 23802768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib treatment in BRAF(V600E/K) advanced melanoma
Number of subjects: 209
Study 21453882 — intervention group
Group type: COMPARATOR
Intervention: 9mg budesonide once daily (OD)
Number of subjects: 343
Study 21453882 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g mesalazine granules OD
Number of subjects: 343
Study 19324592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 23
Study 19324592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16319914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1 mg)
Number of subjects: 100
Study 16319914 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 100
Study 14967075 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (30 mg/m2 weekly for 6 weeks)
Number of subjects: 13
Study 14967075 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab alone (4 mg/kg intravenously on week 1 followed by 2 mg/kg per week thereafter)
Number of subjects: 13
Study 14967075 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus docetaxel combination therapy
Number of subjects: 13
Study 10673248 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) + Aspirin (100 mg)
Number of subjects: 700
Study 10673248 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine (500 mg) + Aspirin (100 mg)
Number of subjects: 700
Study 9084967 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glycopyrrolate
Number of subjects: 13
Study 9084967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8518780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 0
Study 3298410 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-2 recombinant interferon
Number of subjects: 0
Study 31603979 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically increased telomere length (GI-TL)
Number of subjects: 337522
Study 29310055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with training (MTG)
Number of subjects: 45
Study 29310055 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (TG)
Number of subjects: 45
Study 29310055 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45
Study 27321384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum within the first 12 hours after surgery
Number of subjects: 41
Study 27321384 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (control group)
Number of subjects: 41
Study 27321384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum
Number of subjects: 41
Study 25011991 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0
Study 25011991 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 0
Study 22388634 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted atazanavir (ATV/r)
Number of subjects: 201
Study 22388634 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitor (PI/r)
Number of subjects: 201
Study 20052347 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Cycling (WC)
Number of subjects: 109
Study 20052347 — intervention group
Group type: COMPARATOR
Intervention: Non-Weight Cycling (NWC)
Number of subjects: 109
Study 18059580 — intervention group
Group type: EXPERIMENTAL
Intervention: OFTT with P/S ratio of 0.2
Number of subjects: 8
Study 18059580 — intervention group
Group type: EXPERIMENTAL
Intervention: OFTT with P/S ratio of 2.0
Number of subjects: 8
Study 16392537 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive and balance exercise program
Number of subjects: 29
Study 16392537 — intervention group
Group type: COMPARATOR
Intervention: Strengthening program
Number of subjects: 29
Study 12019665 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 20
Study 10588620 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention consisting of two 2‐h group sessions and 1 to 2 individual sessions by a trained nurse and physiotherapist, with a self‐management plan developed.
Number of subjects: 140
Study 10588620 — intervention group
Group type: COMPARATOR
Intervention: Control group (uneducated patients).
Number of subjects: 140
Study 10588620 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention for COPD patients.
Number of subjects: 140
Study 10588620 — intervention group
Group type: COMPARATOR
Intervention: Control group (uneducated COPD patients).
Number of subjects: 140
Study 10319301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of triamcinolone
Number of subjects: 8
Study 1853956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 25 mg b.i.d.
Number of subjects: 13
Study 1853956 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide, 20 mg b.i.d.
Number of subjects: 13
Study 1853956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1853956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 13
Study 1853956 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 13
Study 6193123 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin + Cyclophosphamide + Dactinomycin (BCD)
Number of subjects: 100
Study 6193123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum (CPL)
Number of subjects: 100
Study 6193123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast interferon
Number of subjects: 100
Study 6193123 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy
Number of subjects: 100
Study 6193123 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection after preoperative chemotherapy
Number of subjects: 100
Study 6193123 — intervention group
Group type: COMPARATOR
Intervention: Limb-salvage treatment
Number of subjects: 100
Study 6193123 — intervention group
Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 100
Study 31939556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai-Geiko exercise (EG)
Number of subjects: 19
Study 31939556 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19
Study 30969203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Number of subjects: 194
Study 30969203 — intervention group
Group type: COMPARATOR
Intervention: Control (Imagery Exercises)
Number of subjects: 194
Study 30134964 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) antagonist
Number of subjects: 340
Study 30134964 — intervention group
Group type: COMPARATOR
Intervention: Progestin-primed ovarian stimulation (PPOS)
Number of subjects: 340
Study 23870188 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 226
Study 23870188 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 inserts
Number of subjects: 226
Study 20947591 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 20 mg and fentanyl 20 µg (Group P)
Number of subjects: 50
Study 20947591 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 7.5 mg and fentanyl 20 µg (Group B)
Number of subjects: 50
Study 19723707 — intervention group
Group type: EXPERIMENTAL
Intervention: Three month occupational therapy and physiotherapy programme
Number of subjects: 249
Study 19723707 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 249
Study 17530469 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 13
Study 17530469 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 13
Study 15207440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pet-therapy intervention group (3/week sessions of almost one-hour visit for 6 weeks with a little cat)
Number of subjects: 28
Study 15207440 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activity programs)
Number of subjects: 28
Study 16206676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg twice daily for 5 days)
Number of subjects: 451
Study 16206676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 451
Study 16206676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 9144762 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching the video
Number of subjects: 650
Study 9144762 — intervention group
Group type: EXPERIMENTAL
Intervention: Entering a Quit and Win contest
Number of subjects: 650
Study 9144762 — intervention group
Group type: EXPERIMENTAL
Intervention: Submitting a quit contract
Number of subjects: 650
Study 9144762 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving the booster call
Number of subjects: 650
Study 9144762 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading the Kick It! guide
Number of subjects: 650
Study 9144762 — intervention group
Group type: COMPARATOR
Intervention: Overall intervention use
Number of subjects: 650
Study 7960167 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF toothpaste (1000 ppm F and 1500 ppm F)
Number of subjects: 4294
Study 7960167 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF+TMP toothpaste
Number of subjects: 4294
Study 7960167 — intervention group
Group type: COMPARATOR
Intervention: SMFP toothpaste
Number of subjects: 4294
Study 3676606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 75
Study 3676606 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 75
Study 3676606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 28502060 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ-blocker
Number of subjects: 70
Study 28502060 — intervention group
Group type: COMPARATOR
Intervention: Univent tube (UT)
Number of subjects: 70
Study 27190088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 71
Study 27190088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 24550339 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose albendazole
Number of subjects: 175
Study 24550339 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of albendazole
Number of subjects: 175
Study 24550339 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day regimen of albendazole
Number of subjects: 175
Study 24550339 — intervention group
Group type: COMPARATOR
Intervention: Two-dose regimen compared to single-dose
Number of subjects: 175
Study 24550339 — intervention group
Group type: COMPARATOR
Intervention: Three-dose regimen compared to single-dose
Number of subjects: 175
Study 22203049 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min neuromuscular warm-up programme carried out twice a week during the 11-week study period
Number of subjects: 52
Study 22203049 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 20124502 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exercise Swimming Program (WESP)
Number of subjects: 16
Study 19032722 — intervention group
Group type: EXPERIMENTAL
Intervention: DrugRCT publications from Europe
Number of subjects: 103211
Study 19032722 — intervention group
Group type: COMPARATOR
Intervention: DrugRCT publications from USA
Number of subjects: 103211
Study 19032722 — intervention group
Group type: COMPARATOR
Intervention: DrugRCT publications from Australia/Japan
Number of subjects: 103211
Study 19032722 — intervention group
Group type: EXPERIMENTAL
Intervention: Citations per publication in Europe
Number of subjects: 103211
Study 19032722 — intervention group
Group type: COMPARATOR
Intervention: Citations per publication in USA
Number of subjects: 103211
Study 19032722 — intervention group
Group type: COMPARATOR
Intervention: Citations per publication in Australia/Japan
Number of subjects: 103211
Study 19032722 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional increase in publication output from 1995 to 2004 in Europe
Number of subjects: 103211
Study 19032722 — intervention group
Group type: COMPARATOR
Intervention: Proportional increase in publication output from 1995 to 2004 in USA
Number of subjects: 103211
Study 19032722 — intervention group
Group type: COMPARATOR
Intervention: Proportional increase in publication output from 1995 to 2004 in Australia/Japan
Number of subjects: 103211
Study 15680715 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter treatment of ASA + PFO
Number of subjects: 141
Study 15680715 — intervention group
Group type: COMPARATOR
Intervention: PFO alone
Number of subjects: 141
Study 12847496 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut butter skin contact (0.2 mL pressed flat for 1 minute)
Number of subjects: 30
Study 12847496 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut butter inhalation (surface area of 6.3 square inches 12 inches from the face for 10 minutes)
Number of subjects: 30
Study 12847496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soy butter mixed with histamine for contact, scent masked with soy butter, tuna, and mint for inhalation)
Number of subjects: 30
Study 10411769 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg.kg-1
Number of subjects: 120
Study 10411769 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 50 microg.kg-1
Number of subjects: 120
Study 10411769 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg.kg-1 plus Droperidol 50 microg.kg-1
Number of subjects: 120
Study 8909671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium infusion with spontaneous recovery
Number of subjects: 30
Study 8909671 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 0.05 mg/kg and atropine 0.02 mg/kg
Number of subjects: 30
Study 1498569 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin ophthalmic solution
Number of subjects: 284
Study 1498569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 6739537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg FK 33‐824
Number of subjects: 16
Study 6739537 — intervention group
Group type: COMPARATOR
Intervention: 20 mg diazepam
Number of subjects: 16
Study 30497955 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated nursing management model plus routine outpatient care
Number of subjects: 367
Study 30497955 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient care
Number of subjects: 367
Study 29161695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block
Number of subjects: 40
Study 29161695 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic infiltration (LAI)
Number of subjects: 40
Study 27838537 — intervention group
Group type: EXPERIMENTAL
Intervention: HA, CS, curcumin and quercetin per os
Number of subjects: 145
Study 27838537 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estrogens
Number of subjects: 145
Study 27838537 — intervention group
Group type: EXPERIMENTAL
Intervention: HA, CS, curcumin and quercetin per os with local estrogens
Number of subjects: 145
Study 24503333 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention focusing on disidentification
Number of subjects: 0
Study 24503333 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention focusing on awareness and acceptance
Number of subjects: 0
Study 24503333 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention (distraction)
Number of subjects: 0
Study 23437698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologic rehabilitation (stage 2)
Number of subjects: 58
Study 23437698 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 58
Study 20714373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 microg
Number of subjects: 1990
Study 20714373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 10 microg
Number of subjects: 1990
Study 20714373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1990
Study 17382476 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg/kg rFVIIa administered at first skin incision and a second dose at 90 min later
Number of subjects: 18
Study 17382476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15705619 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 60
Study 15705619 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 60
Study 15705619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICSI and IVF
Number of subjects: 60
Study 11923489 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiluted vaccine (10^7.8 pfu/ml)
Number of subjects: 60
Study 11923489 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10 dilution (10^6.5 pfu/ml)
Number of subjects: 60
Study 11923489 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:100 dilution (10^5.0 pfu/ml)
Number of subjects: 60
Study 11923489 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with vesicles
Number of subjects: 60
Study 11923489 — intervention group
Group type: COMPARATOR
Intervention: Subjects without vesicles
Number of subjects: 60
Study 9892064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, a 5-HT uptake inhibitor, administered orally.
Number of subjects: 0
Study 9892064 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control group).
Number of subjects: 0
Study 7634976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally applied sulindac (53 mg/day average)
Number of subjects: 15
Study 7634976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally applied sulindac (67 mg/day average)
Number of subjects: 15
Study 7634976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally applied sulindac
Number of subjects: 15
Study 2229816 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylated hydroxyanisole (BHA)
Number of subjects: 2
Study 2229816 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylated hydroxytoluene (BHT)
Number of subjects: 2
Study 2229816 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet without BHA and BHT
Number of subjects: 2
Study 338393 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 4 mg
Number of subjects: 120
Study 338393 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 8 mg
Number of subjects: 120
Study 338393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg
Number of subjects: 120
Study 338393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31989379 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND)
Number of subjects: 463
Study 31989379 — intervention group
Group type: COMPARATOR
Intervention: No completion axillary lymph node dissection (ALND)
Number of subjects: 463
Study 30284350 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 19
Study 30284350 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 19
Study 28869987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP goal (120 mm Hg)
Number of subjects: 6662
Study 28869987 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP goal (140 mm Hg)
Number of subjects: 6662
Study 25907149 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruistic behavior by P
Number of subjects: 0
Study 25907149 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0